2 ) or obese (BMI ≥30 kg/m 2 ) will surpass 1.5 billion. 1 Excess body weight is an independent risk factor for mortality. 2 Among the constellation of weightrelated comorbidities that bring the greatest burden for obese patients and their healthcare providers are diabetes mellitus and cardiovascular disease (CVD). Obesity, diabetes mellitus, and CVD cannot be successfully addressed in isolation; therefore, weight loss achieved by any means is a key component of comprehensive cardiovascular care. 3, 4 Dietary, Lifestyle, and Pharmacological
Management of Obesity
Obesity prevention is the ideal scenario. However, in the midst of an obesity pandemic, treatment options are essential. The initial approach must always address lifestyle and dietary choices, which contribute so greatly to the current obesogenic environment. A healthy lifestyle is easily prescribed but challenging to maintain. Stalonas et al 5 demonstrated not only that patients who diet usually regain their lost weight within 5 years but also that the average subject was 1.5 lb heavier at follow-up than on entering the program. A recent systematic review of dietary and lifestyle options demonstrated no conclusive evidence for sustainable weight loss. 6 However, it is possible for intensive lifestyle coaching to achieve moderate weight loss, as demonstrated by Appel et al. 7 Of their 392 obese subjects, those receiving in-person support lost a mean of 5.1 kg (P<0.001 for comparison with control subjects) and those receiving only telephone/Internet support lost a mean of 4.6 kg (P<0.001 for comparison with control subjects) at 24 months. The superiority of bariatric surgery over pharmacological and lifestyle interventions in modulating weight, hyperglycemia, and hypertriglyceridemia has been demonstrated by meta-analysis. 8 Few studies have directly compared medical and surgical management of obesity, but 2 head-to-head comparisons highlight the differential impacts. Morbidly obese subjects were assigned to gastric bypass surgery (n=80) or intensive lifestyle intervention (n=66), with the 76 surgical completers and 63 lifestyle completers achieving 1-year weight losses of 30±8% and 8±9%, respectively. 9 Diabetes mellitus and hypertension remission rates were significantly higher in the surgery group (70% versus 33% [P=0.027] and 49% versus 23% [P=0.016], respectively). Andersen et al 10 randomized 57 patients to gastroplasty or a very-low-calorie diet; at 5 years, 8 of 27 gastroplasty patients (30%; 95% confidence interval [CI], 14-50) had maintained >10-kg weight loss compared with 5 of 30 diet-only patients (17%; 95% CI, .
Several pharmacological agents have been marketed for weight loss assistance, although the degree of weight loss in excess of placebo tends to be modest, generally lying in the −2-to −6-kg range. 11 After the withdrawal of sibutramine from the American market, the sympathomimetic drugs with established and ongoing roles in the short-term treatment of obesity are phentermine, diethylpropion, benzphetamine, and phendimetrazine. 12 Use is generally limited to 12 weeks, and potential side effects include hypertension. Two newer agents have recently gained Food and Drug Administration approval. Lorcaserin, a selective 5-HT 2C receptor agonist, was approved under the trade name Belviq in June 2012. It is intended to promote satiety in individuals with a BMI >30 kg/m 2 or >27 kg/m 2 plus at least 1 obesity-related comorbidity and is contraindicated in pregnancy. An extended-release preparation combining phentermine and topiramate (an antiepileptic) was subsequently approved in July 2012 as Qsymia. The standard dose contains 7.5 mg phentermine and 46 mg topiramate; there is also a high-dose 15-mg/92-mg option. Contraindications include pregnancy, glaucoma, hyperthyroidism, and unstable heart disease or stroke within the prior 6 months.
An alternate medication option is orlistat, which inhibits pancreatic lipases, thus increasing the proportion of dietary fat that is incompletely hydrolyzed and fecally excreted. It can be used for up to 2 years and achieved a 2.9-kg (95% CI, 2.5-3.2) mean weight reduction beyond placebo at 1 year in a meta-analysis of 15 studies. 13 In obese individuals with diabetes, orlistat also decreases hemoglobin A 1c (HbA 1c ) at 1 year compared with placebo. 14 Other medications that may have a role in supporting weight loss include antidepressants such as venlafaxine, bupropion, and fluoxetine, as well as diabetes medications such as metformin and the glucagonlike peptide-1 (GLP-1) analogs exenatide, pramlintide, and liraglutide. At the time of writing, the Food and Drug Bariatric surgery is currently the most effective strategy for attaining significant and sustainable weight loss. Dr Richard Varco (Minnesota) performed the first jejunoileal bypass in 1953, specifically to induce weight loss from malabsorption. Although fraught with nutritional complications, this procedure achieved marked weight reduction and dramatically improved the lipid profiles of severely hyperlipidemic patients. 16 The jejunoileal bypass was subsequently modified and refined to reduce malabsorptive complications while retaining the weight loss and lipid-lowering capabilities. Hence, procedures such as the biliopancreatic diversion (BPD; Dr Scopinaro) and duodenal switch (DS; Dr Marceau) emerged, followed by procedures with a "restrictive," or gastric volume reduction, component, including the Roux-en-Y gastric bypass (RYGB) and vertical-banded gastroplasty. More recent developments are pure gastric volume reduction operations such as adjustable gastric banding (AGB) and sleeve gastrectomy (SG; see the Figure) . RYGB, which combines gastric volume reduction and malabsorptive functions, was the most popular weight loss procedure in the United States and Canada as of 2008, being performed in 51% of 220 000 of surgical procedures. 17 Conversely, gastric banding was more popular outside North America, with 43.2% AGBs versus 39% RYGBs in Europe and 82.5% AGBs versus 9.1% RYGBs in Asian and Pacific centers. Vertical-banded gastroplasty, the commonest surgery in the Swedish Obese Subjects (SOS) studies, is now rarely performed in the United States because it encourages maladaptive eating behavior. 18 Candidacy for weight loss surgery is an evolving field, although the original 1991 National Institutes of Health guidelines recommending surgical intervention in patients with BMI >40 kg/m 2 or BMI ≥35 kg/m 2 plus significant obesityrelated comorbidities continue to underline current practice (Table 1) . 19, 20 The International Diabetes Federation proposed the newest additions to bariatric candidacy in 2011. They support consideration of surgery for patients with type 2 diabetes mellitus (T2DM) and obesity (BMI >30 kg/m 2 ) who are failing to achieve International Diabetes Federation treatment targets with optimal medical therapy alone, especially in the presence of additional cardiovascular risk factors. 20 The importance of incorporating bariatric surgery into a wider-reaching strategy including strict preoperative and postoperative dietary and physical activity modifications is comprehensively reviewed in the 2011 American Heart Association scientific statement on bariatric surgery and cardiovascular risk factors. 21 Postoperative weight loss is typically expressed as a percentage of excess weight, referring to the difference between the actual and ideal weights for an individual. The primary goal of bariatric procedures is weight loss, and an excess weight lost (EWL) ≥50% is considered a surgical success. 23 reported a peak in weight loss at 1 to 2 years postoperatively followed by a small weight regain in all surgical procedure subgroups and subsequent weight stabilization after 8 to 10 years.
As bariatric surgery has become increasingly accepted among both physicians and patients as a mainstream strategy for weight loss over recent decades, the actual weight loss has almost been overshadowed by the impact on obesity-related comorbidities, as outlined in Table 2. 22-41 However, these multisystem health benefits must be carefully weighed against the potential for surgical complications. Bariatric surgical risk has declined steadily with the widespread adoption of minimally invasive techniques and advanced medical device technology, with the majority of cases now being performed Anatomic modifications as created in the 4 most common bariatric surgery procedures. Gastric banding involves placement of an adjustable gastric band around the proximal part of the stomach. The band is fixed in position by inserting plication sutures anteriorly. The band can be adjusted/tightened over time by injecting fluid into the subcutaneous port connected to the band. Sleeve gastrectomy involves reducing gastric volume by 75% to 80% by resecting the stomach alongside a 30F endoscope beginning 3 cm from the pylorus and ending at the angle of His. The Roux-en-Y gastric bypass involves creation of a 15-to 20-mL gastric pouch, a 150-cm Roux limb, and a 50-cm biliopancreatic limb. The biliopancreatic diversion procedure includes a distal gastrectomy with long Roux-en-Y reconstruction, where the enteroenterostomy is placed ≈50 cm proximal to the ileocecal valve. Both the volume of the gastric remnant and the length of the alimentary limb can be modified to suit the patient's weight loss goal.
by guest on October 4, 2017 http://circ.ahajournals.org/ Downloaded from laparoscopically. 42, 43 Rates of conversion to open procedures are in the range of 0% to 5.7%, with the highest rates seen in the most complex malabsorptive procedures or revisional surgeries. [44] [45] [46] 
Risks and Complications
In the first meta-analysis of published mortality data after bariatric surgery in 2004, Buchwald 47 A 0.3% 30-day mortality rate was also reported by the Longitudinal Assessment of Bariatric Surgery (LABS) consortium in 4776 patients. 48 The LABS composite end point of death, venous thromboembolism, surgical reintervention, or failure to discharge by postoperative day 30 occurred in 4.1% of patients (1.0% of laparoscopic adjustable gastric banding [LAGB], 4.8% of laparoscopic RYGB, 7 .8% of open RYGB), which is encouraging considering the deconditioned and medically comorbid nature of this patient group.
Despite these reassuring numbers, bariatric surgery patients continue to be at risk for a number of potentially fatal postoperative complications that deserve careful consideration. Venous thromboembolism remains the leading cause of post-bariatric surgery mortality, with a published incidence of 0.34%. 49, 50 Surgeons seek to minimize this risk with perioperative mechanical and pharmacological prophylactic measures. 51 Gastrointestinal leak is the most feared technical complication. Rates range from 1% for LAGB to 2% for RYGB and SG. [52] [53] [54] The majority of leaks originate at staple 55 Additional contributors to postoperative morbidity and mortality include sepsis resulting from anastomotic dehiscence, respiratory failure, and postoperative cardiac events, which are discussed separately below.
Other complications are unique to the specific procedure. The dumping syndrome is a constellation of gastrointestinal and vasomotor symptoms such as abdominal bloating, vomiting, diaphoresis, and dizziness associated with gastric volume reduction surgery. It is frequently attributed to rapid gastric emptying, although a hormonal component is likely. 56 Dietary modifications such as reducing carbohydrates and avoiding liquids for 30 minutes after a meal or the use of octreotide can help. Restrictive operations are also susceptible to stenosis or stricture formation. Edema can cause acute partial or complete obstruction; in late obstruction, the cause is local fibrosis. Anastomotic strictures usually present in the first postoperative month after RYGB, and most can be managed endoscopically with balloon dilatations. 57 Another delayed complication of bariatric surgery is ulceration near the gastrojejunal anastomosis of an RYGB or a BPD. These marginal ulcers are consequent to exposure of the unprotected jejunal mucosa to gastric acidity. Proton pump inhibition is sufficient for the majority of cases, with surgical intervention rarely required for refractory ulceration. 58 Gastric band patients are inherently predisposed to band slippage, leakage, and erosion, resulting in reintervention rates as high as 20%. 59 Incisional and internal herniation can complicate open and laparoscopic procedures, respectively. Given that presenting symptoms and clinical signs may be subtle, a high index of suspicion is critical for timely surgical exploration, reduction of the hernia, and resection of nonviable bowel. 60, 61 Deficiency of essential vitamins and minerals is common after RYGB and BPD and on rare occasions may be life threatening (eg, thiamine deficiency encephalopathy). 62 The multidisciplinary team should implement dietary supplementation immediately after the procedure, including the mostly commonly depleted micronutrients vitamins D and B 12 , folic acid, iron, and calcium. 63 Rates of vitamin and mineral deficiencies are highly variable, but 1 study of 298 RYGB subjects receiving a variety of Roux limb lengths and anastomotic locations found the following deficiency prevalences at 2 to 3 years postoperatively: iron deficiency, 45% to 52%; vitamin B 12 deficiency, 8% to 37%; calcium deficiency, 10%; and vitamin D deficiency 51%. 64 A metaanalysis from Maggard et al 65 concluded that ≈20% of bariatric surgery patients will experience a surgical complication or side effect, although the likelihood is much lower in laparoscopic than open procedures. Table 3 outlines the rates of RYGB complications that surgical candidates are counseled on at our institution.
Patient Selection and Optimization
In addition to the basic criteria for bariatric surgery candidacy (Table 1) , patients presenting for multidisciplinary evaluation are also assessed for preexisting comorbidities (particularly thromboembolism, untreated obstructive sleep apnea, coronary artery disease [CAD], or heart failure), micronutrient deficiencies, psychiatric diagnoses that may affect the patient's ability to follow the postsurgical dietary program, and active substance abuse. It should also be remembered that male patients and those ≥60 years of age are at particular risk for complications. 66 Well-informed, motivated patients with a history of adherence to medical therapy and strong social support are ideal candidates. Selection of the optimal surgical procedure for each individual is a decision process that factors in patient preference, the degree of perioperative risk acceptable to the individual, the degree of weight loss targeted, the presence of prior gastrointestinal conditions or interventions, and existing comorbidities. In general, patients with a BMI <40 kg/m 2 may be more suited to SG or LAGB, whereas surgery with a malabsorptive component such as laparoscopic RYGB or BPD with or without DS is usually preferable in patient with a BMI >40 kg/m 2 . An additional Moderate Arrhythmia without hemodynamic instability, 2%; abdominal hemorrhage or anemia without a clear source, requiring blood transfusion, 5%
Wound infection, 3%; pneumonia, 4%; nausea and vomiting requiring inpatient admission for intravenous volume repletion, 8%
Malnutrition of vitamins or minerals, up to 50%; dumping syndrome, up to 75% but clinically significant in <5%; gallstones, 2%; anastomotic ulcer, 8%; anastomotic stricture, 7%; stomal stenosis, 5%
Severe Reoperation for abdominal hemorrhage, 2%; anastomotic leak with/without sepsis, 2%; reoperation for any reason, 6%; myocardial infarction, 0.5%; unstable arrhythmia or cardiac arrest, <1%
Pulmonary embolus, respiratory failure, or other potentially fatal medical complication, 0.5% Herniation or small bowel obstruction, 4%
Generalized overall risk of mortality to postoperative day 30, ≈0.3% Generalized overall risk of mortality from postoperative day 30 to 2 y, ≈0.3%
Sources: Podnos et al, 53 Schauer et al, 67 and Buchwald et al.
consideration, even for less obese patients, is the presence of metabolic consequences of obesity. T2DM is an indication to consider RYGB even in patients with a BMI in the 30-to 40-kg/m 2 range, 67 and BPD/DS may offer superior effects on insulin homeostasis in the superobese (>50 kg/m 2 ) with difficult-to-control diabetes mellitus. 68 Standard preoperative testing includes basic blood tests (particularly to identify occult anemia, hypothyroidism, or renal/hepatic dysfunction), baseline ECG, chest x-ray, pulmonary function testing, upper endoscopy if suspicion exists for a gastric pathology, and polysomnography if obstructive sleep apnea is suspected by history. 69 If Helicobacter pylori infection is present, preoperative eradication is advisable. Abdominal ultrasound may be performed to detect cholelithiasis and to allow the surgeon to consider concomitant cholecystectomy; if hepatic steatosis or cirrhosis is suspected, intraoperative liver biopsy may be indicated. 70 Although identification of comorbidities preoperatively is crucial, most are not a contraindication to proceeding with surgery. The Utah Obesity Study excluded only 1% of eligible subjects because of medical conditions. 71 Obstructive sleep apnea should be managed with aggressive use of perioperative continuous positive airway pressure, and asthma or other lung conditions must be optimized. Baseline micronutrient deficiencies, commonly of vitamin D and iron, should be corrected preoperatively. Patients are encouraged and supported to lose 5% to 10% of their initial weight preoperatively, which can significantly reduce operating room times and lengths of stay for patients with BMI >50 kg/m 2 .
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Screening for and optimization of CAD before bariatric surgery is an area of variable practice. The 2009 AHA guidelines on cardiovascular evaluation and management of severely obese patients undergoing surgery offer very useful guidance for preoperative cardiac screening. 73 Essentially, in patients with 1 CVD risk factor or known stable CAD, further cardiac assessment is not indicated. In individuals with >1 risk factor who are unable to demonstrate good functional capacity or who have cardiovascular symptoms on exertion, stress testing should be considered. Difficulties arise because both single-photon emission computed tomography imaging and stress echocardiogram have reduced accuracy in the obese population, principally as a result of reduced specificity and sensitivity, respectively. 74 Noninvasive stress testing must usually be performed pharmacologically in this deconditioned population, and a proportion of dobutamine echocardiograms will be nondiagnostic as a result of suboptimal stress. Coupled with the fact that attenuation correction and combined supine/ prone protocols significantly reduce the rate of false-positive single-photon emission computed tomograms in obesity, single-photon emission computed tomography (or position emission tomography when available) 75 is usually the preferred modality. Alternative strategies include stress transesophageal echocardiograms 76 or proceeding directly to cardiac catheterization in high-risk individuals such as those with ≥3 risk factors or a history of cardiovascular events.
Coronary revascularization before noncardiac surgery has not been shown to enhance survival, so preoperative stress test testing is recommended only when it will change management. 77 It remains unclear how an asymptomatic pre-bariatric surgery patient, albeit usually with poor functional capacity, with a positive stress test should be managed; hence, testing in the absence of risk factors should be discouraged. 78 Perioperative β-blockade is commonly prescribed for patients with CAD or a positive stress, although the risk-to-benefit ratio in the obese population is unknown. 73 As outlined below, limited data suggest that bariatric surgery can be performed safely in heart failure patients who are medically optimized preoperatively. 77 Anesthesia for bariatric patients has become an area of subspecialty expertise, developing methods in airway, hemodynamic, glycemic, and analgesic management specific to the obese population. 18 Brief hypotension is seen in 5% to 10% of patients on institution of the pneumoperitoneum and steep reverse-Trendelenburg positioning, which usually responds briskly to intravenous fluids. 79 
Metabolic Changes With Bariatric Surgery
Two-year data from SOS, in which the majority of patients underwent vertical-banded gastroplasty, revealed that 72% of surgical patients achieved freedom from preexisting diabetes mellitus compared with 21% of control subjects (P<0.001). 23 At 10 years, diabetes mellitus remained in remission in 36% of the surgical group and 13% of control subjects (P=0.001). These findings were mirrored in the 135 246-patient metaanalysis by Buchwald et al 80 that demonstrated complete resolution of diabetes mellitus (defined as off diabetes medications with fasting blood glucose <100 mg/dL or HbA 1c <6%) for 80.3% of patients with <2 years' follow-up and 74.6% of patients with ≥2 years' follow-up. Adams et al 81 recently described 75% diabetes remission at 2 years and 62% remission at 6 years among 418 RYGB patients with 92.6% follow-up; the remission odds ratio compared with 2 control groups was 16.5 (95% CI, 4.7-57.6; P<0.001). However, the definition of diabetes "remission" has been variable across studies. Hence, criteria have been formulated by which a diabetes "cure" can now be defined: Complete remission requires an HbA 1c or fasting glucose in the normal range without pharmacological therapy or ongoing procedures of at least a 1-year duration. 82 A 2012 SOS publication reported on the potential for bariatric surgery to prevent diabetes mellitus, with a 78% reduction in T2DM incidence over a median of 10 years after bariatric surgery compared with a matched group of obese subjects receiving standard medical care. 83 Results were recently reported from a prospective, randomized trial evaluating the efficacy of intensive medical therapy alone versus medical therapy plus RYGB or SG for patients with uncontrolled T2DM and BMIs ranging from 27 to 43 kg/m 2 . 67 The 150 subjects in Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) had a mean age of 49±8 years and a mean baseline HbA 1c of 9.2±1.5%, and 66% were female. The primary end point was the proportion of patients with HbA 1c <6.0% at 12 months. Fifty subjects were randomized to each of the 3 study groups-medical therapy alone, RYGB, or SG-with a 93% follow-up rate. The primary end point was achieved by 12% of the medical therapy group compared with 42% of the RYGB group (P=0.002 compared with medical therapy alone) and 37% in the SG group (P=0.008 compared with February 26, 2013 medical therapy alone). There was improved glycemia in all 3 groups at 1 year, with a mean HbA 1c of 7.5±1.8% in the medical therapy group, 6.4±0.9% in the RYGB group (P<0.001), and 6.6±1.0% in the SG group (P=0.003). The surgical subjects experienced greater mean weight loss (−29.4±9.0 kg for RYGB and −25.1±8.5 kg for SG) compared with the medically treated subjects (−5.4±8.0 kg; P<0.001 for both comparisons). Medications for diabetes mellitus, hyperlipidemia, and hypertension were significantly reduced in both surgical groups but were increased in medically treated participants during the study. Specifically, insulin use remained high at 12 months (38%) in the medical therapy group but fell to 4% in the RYGB group and to 8% in the SG group (P<0.001 for both comparisons). Reoperation was required in 4 surgical subjects, but there were no mortalities or life-threatening complications. These biochemically defined outcomes, along with 2 similar randomized trials, 84, 85 add further weight to the potential for surgical interventions to significantly affect the metabolic consequences of obesity and to provide a mechanism for the modulation of future cardiovascular event rates.
The pathophysiology of metabolic responses to bariatric procedures is still incompletely understood. The rate of change of glucose homeostasis is quite remarkable, with many malabsorptive surgery patients showing a rapid decrease in their insulin requirement over the first postoperative week. There are interesting improvements in inflammatory and adipokine profiles postoperatively, which may have a role in the observed improvements in glucose and lipid homeostasis. Circulating C-reactive protein and interleukin-6 levels have been observed to fall by as much as 81% and 23%, respectively, paralleling the improvements in insulin sensitivity. 86 Gastric bypass and SG lead to rapid reductions in leptin levels as early as 1 week postoperatively, with ongoing decreases until 12 months postoperatively; meanwhile, adiponectin increases progressively over this time. 87 Although there is evidence supporting a key role for adipokines such as leptin, resistin, and adiponectin in the metabolic effects of bariatric surgery, some authorities place greater emphasis on the gut hormones that regulate appetite and satiety as the critical mediators of post-RYGB weight loss and improved insulin sensitivity. Ghrelin, peptide YY, glucose-dependent insulinotropic peptide (GIP), and GLP-1 are the gut hormones of particular interest. GLP-1 and GIP are incretins, a family of gastrointestinal hormones that stimulate postprandial β-cell insulin release, inhibit glucagon, slow gastric empting, and promote weight loss. GLP-1 is cosecreted with peptide YY by enteroendocrine L cells of the ileum and colon in response to a carbohydrate load. Both GLP-1 analogs, and also the dipeptyl peptidase-4 inhibitors (sitagliptin, saxagliptin, linagliptin, vildagliptin) that deter GLP-1 and GIP degradation, are new pharmacological agents for T2DM. RYGB patients demonstrate an immediate 3-to 5-fold increase in postprandial GLP-1 and peptide YY levels postoperatively, which precedes significant weight loss and is independent of caloric restriction. 88 Restored GLP-1 levels may be a mechanism for the recovery of earlyphase insulin secretion in response to oral carbohydrates. Ghrelin responses after RYGB are more heterogeneous and are therefore less likely to explain reduced appetite and improved glucose homeostasis. 89 It is likely that both duodenal exclusion (the foregut hypothesis) and the rapid delivery of nutrients to the L cells of the small intestine owing to the accelerated transit through the proximal bypassed section of the gut (the hindgut hypothesis) are contributors to the restoration of gut hormone profiles, satiety, and euglycemia after RYGB.
Although the signaling mechanisms are still under investigation, it is now clear that β-cell glucose sensitivity increases in the early days and weeks after malabsorptive bariatric surgery independently of weight loss and without significant alterations in tissue insulin sensitivity. 90 Fatty substrates are released into the circulation and promote lipid oxidation, which prompts weight loss. This is followed by a gradual improvement in peripheral and hepatic insulin sensitivity that is in proportion to the degree of weight lost. During the 12 months after RYGB, the likelihood and extent of diabetes remission is dependent on the degree of preoperative β-cell dysfunction. 91 In large clinical studies, the eventual degree of weight loss generally correlated with the extent of metabolic benefit derived from surgery. EWL paralleled the magnitude of biochemical responses in studies by Schauer et al 92 
Comparison Among Bariatric Procedures
Just as the efficacy of surgical weight loss favors procedures with a malabsorptive function, so too does the degree of metabolic adaptation, as outlined in Table 4 . [94] [95] [96] [97] [98] [99] [100] [101] [102] Head-tohead comparisons of metabolic impact confirm the superiority of malabsorptive over gastric volume reduction surgeries, albeit at the expense of a greater perioperative risk and higher likelihood of malnutrition. However, meta-analyses of the LAGB versus RYGB data highlight the excess of late (≥30 days) complications and the need for reoperation for LAGB patients. 54 One study following up patients to a median of 16.2 months showed a 78% LAGB late complication rate compared with 28% in RYGB (P<0.05). 103 Weight loss outcomes consistently favor RYGB by a margin of ≈25% and show persistence to 5 years postoperatively (EWL, 47% versus 67%; P<0.001), 104 with correspondingly superior rates of diabetes, hypertension, and hyperlipidemia remission for RYGB than LAGB patients at 3 years. 105 SG is a gastric volume reduction procedure that is growing in popularity and is slightly more technically demanding. The weight loss offered by SG is superior to that of LAGB at 3 years (66% versus 48% EWL; P=0.0025), but the severity of early complications is greater than with LAGB. 96 SG and RYGB appear to have nearly equivalent impacts on weight and glucose homeostasis at 3 months 106 and 1 year. 107 In comparisons between the procedures with malabsorptive functions, the less commonly performed BPD and DS generally outperform RYGB in terms of weight loss and diabetes resolution. 85 Among 350 patients with BMI ≥30 kg/m 2 (DS, n=198; RYGB, n=152), diabetes, hypertension, and dyslipidemia resolution was greater at 36 months for DS (diabetes mellitus, 100% versus 60%; hypertension, 68.0% versus 38.6%; dyslipidemia, 72% versus 26.3%), with the superior resolution of metabolic comorbidities being independent of weight loss. 108 In a randomized trial comparing DS (n=29) with RYGB (n=31), DS achieved greater weight loss, greater cholesterol improvement, and more adverse events, although reductions in blood pressure and mean concentrations of glucose and insulin showed no difference between surgical groups. 109 DS appears to achieve euglycemia without a rise in insulin levels and therefore may be a preferable procedure when the primary indication is diabetes management. 68 There are limited head-to-head data comparing BPD with RYGB, but weight loss with BPD is superior to that with LAGB, although rates of diabetes and hypertension improvement at 5.4 years did not differ in 1 study. 110 Scopinaro et al 111 reported a more dramatic effect of BPD on diabetes mellitus among 443 severely obese patients compared with the data in the literature on gastric bypass. The proportion of patients with fasting serum glucose ≤110 mg/dL on free diet and with no therapy was 74% at 1 month, 97% at 1 and 10 years, and 91% at ≥20 years, with the 26% of patients not attaining remission at 1 month being those with the most severe preoperative T2DM. When performed as revisional surgery after a failed LAGB, BPD/DS offers slightly greater weight loss at 18 months but at a cost of greater complications and a longer operative time.
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Cardiovascular Outcomes of Bariatric Surgery
The overall impact of bariatric surgery on CVD risk factors is well documented. Across 19 543 surgical subjects (mean age, 42 years; 76% female) with a mean follow-up period of 57.8 months (range, 3-176 months), hypertension remitted or resolved in 63% of affected subjects, dyslipidemia in 65%, and diabetes mellitus in 73%. 113 It must be emphasized that the majority of trials assessing the cardiovascular impact of bariatric surgery have thus far used only cardiovascular risk end points such as hypertension, diabetes mellitus, hyperlipidemia, and/or inflammatory markers, with far fewer reporting actual cardiovascular events or mortality postoperatively. There must now be a shift in the design of bariatric surgery trials toward the pursuit of longer-term data on actual cardiovascular events, cardiovascular mortality, and all-cause mortality. Additionally, such studies should ideally be randomized. At this point, it remains possible that features specific to obese patients who pursue a surgical intervention compared with those who do not opt for surgery are confounding the relationship between bariatric surgery and cardiovascular outcomes. Randomized, controlled trials examining cardiovascular or diabetes end points thus far have been very limited in sample size. 67, 84, 85, 109, 114, 115 The existing studies reporting actual cardiovascular events or mortality outcomes after bariatric surgery merit further attention. A summary of the patient characteristics and major outcomes in these 14 studies is presented in Table 5 . [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] Despite the absence of randomized, controlled trials, the growing body of data on hard outcomes in obese patients who undergo weight loss surgery compared with matched nonsurgical control subjects broadly supports a cardiovascular event and all-cause mortality benefit conferred by bariatric surgery. The largest and most convincing outcome studies come from Flum and Dellinger, 118 Adams et al, 25 Busetto et al, 122 and Sjöström et al, 3 with follow-up periods ranging 4.4 to 14.7 years. Each of these studies used an obese nonsurgical control cohort matched on features such as age, sex, and baseline BMI whose outcomes were compared with those of the surgical study group. The modest short-to long-term survival benefit demonstrated by Flum and Dellinger 118 persisted after propensity matching of the 2 groups; the odds of survival at 5 years was 59% was higher in surgical group (3328 gastric bypass patients) than in the nonsurgical control subjects (odds ratio, 1.59; 95% CI, 1.49-1.72). The 2007 study by Adams et al 25 demonstrated 40% lower all-cause mortality in the surgical group of 7925 RYGB patients (adjusted hazard ratio, 0.60; 95% CI, 0.45-0.67; P<0.001). In the Busetto et al 122 study, survival was 60% higher in their surgical cohort (P=0.0004) of 821 LAGB patients. The SOS group has the longest outcomes follow-up at a median of 14.7 years. Cardiovascular mortality in the surgical group was significantly lower than for control subjects (adjusted hazard ratio, 0.47; 95% CI, 0.29-0.76; P=0.002) despite the greater prevalence of smoking and higher baseline weights and blood pressures in the surgical cohort. The SOS study has formed the basis of much of our current understanding of medium-and long-term outcomes after bariatric surgery despite the fact that the majority of their surgical cohort received vertical-banded gastroplasty, a gastric volume reduction procedure that is now rarely performed in the United States. Therefore, it is significant that the aforementioned studies featuring large cohorts of RYGB subjects corroborate the all-cause mortality benefit of Sjöström et al. 3 However, the studies detailed in Table 5 give contradictory evidence for the influence of baseline patient characteristics on post-bariatric surgery outcomes. Flum and Dellinger 118 concluded that advancing age and male sex were associated with increased mortality risk; similarly, advancing age, male sex, and greater BMI correlated with death in the Busetto 125 There are also contradictions between the outcome studies in their implications as to which obese individuals hold the potential for the greater mortality benefit after surgical intervention. Sowemimo et al 121 saw the greatest surgical benefit in patients <55 years of age and those whose initial BMI exceeded 50 kg/m 2 . However, it was the degree of baseline insulin resistance rather than the initial BMI that was most predictive of cardiovascular benefit in the study by Sjöström et al. 3 Among the 14 outcome studies listed, 2 studies suggested an absence of benefit on all-cause mortality. The 2012 study of Adams et al 81 observed 2.9% mortality among the 418 RYGB subjects compared with 3.3% mortality for the 418 obese patients who sought but did not undergo surgery and 0.9% in the 321 population sample control subjects. None of the deaths in the RYGB group occurred within 30 days of surgery, but there was an excess of deaths resulting from suicide in this surgical cohort. The degree of propensity score adjustment was judged to have adequately corrected for the baseline intergroup differences, but the relative risk of cardiovascular death between subjects and control subjects was not further analyzed. Detailed matching of subjects and control subjects was performed by Maciejewski et al, 124 who retrospectively reviewed survival data of veterans who had undergone bariatric surgery compared with control subjects who were untreated for obesity. The 2-and 6-year crude mortality rates were significantly lower for the operative cohort (2.2% versus 4.6% [P<0.001] and 6.8% versus 15.3% [P<0.001], respectively), but when propensity-score matching and Cox regression analyses were performed, the significance of the surgical mortality benefit was lost. The possibility remains that these adjustment strategies were more accurate than those used by other studies that reached the opposite conclusion and supported a surgical survival benefit. However, this cohort of obese veterans is quite dissimilar to the typical bariatric surgery candidate, with a predominantly male, older demographic (mean age, 49.5±8.3 years) and a relatively high 30-day postoperative mortality rate (1.29%). The implications of this study remain unclear in the context of the positive outcome studies described in Table 5 , but the Maciejewski et al 124 data carry an important message concerning optimal patient selection for operative intervention and the potential pitfalls of generalizing between dissimilar surgical cohorts.
Left Ventricular Dysfunction, Heart
Failure, and Bariatric Surgery A range of cardiac imaging techniques are providing insights into the potential for surgical weight loss to improve myocardial structure, diastolic function, and possibly systolic function. Obesity is a key risk factor for left ventricular (LV) hypertrophy and diastolic dysfunction. [126] [127] [128] As demonstrated in cohorts of 16 to 60 obese patients, there can be improvements in ventricular mass and diastolic function in the 3 months to 3.6 years after bariatric surgery in patients without baseline clinical cardiac disease. 110, [129] [130] [131] [132] The most convincing improvements are seen in LV mass and mass index, E/A ratio, and isovolumic relaxation time. Importantly, the LV mass regression appears to be independent of postoperative systolic blood pressure changes. 113, 129 There is also a growing role for cardiac magnetic resonance imaging in defining the structural and functional cardiac changes with weight loss. Thirty obese subjects without cardiac risk factors underwent magnetic resonance imaging at baseline and 1 year after weight loss (surgical or dietary). 133 The LV absolute mass fell by 10%; right ventricular mass fell by 40%; and 3-dimensional calculations of LV end-systolic volume, stroke volume, and cardiac output showed significant reductions after weight loss. It is yet to be determined whether other cardiac structural changes associated with obesity such as increased epicardial fat, fatty infiltration of myocardium, or increased interstitial fibrosis associated with obesity also regress after successful bariatric surgery.
An echocardiographic study evaluating systolic and diastolic function in 41 SOS gastroplasty subjects reported favorable effects of bariatric surgery on the LV ejection fraction (LVEF). 134 Despite a significant difference between LVEFs in the surgical and obese control patients at 1 year, the mean baseline and follow-up LVEFs in both groups were >50%, so the positive effect of surgery on LVEF was not clinically meaningful. More sensitive echocardiographic techniques than LVEF are now available for detecting changes in systolic function; 2-dimensional speckle tracking-derived strain and strain rate imaging have highlighted the subclinical systolic dysfunction that can be associated with obesity. 135, 136 Thirteen obese patients with LVEFs >40% demonstrated regression of myocardial deformability abnormalities at 6 to 24 months after bariatric surgery. 137 Several cross-sectional and prospective studies have demonstrated a strong and independent association between increased BMI and risk of heart failure. 138, 139 A prospective Framingham study of 5881 participants stratified by BMI at enrollment found that the risk of clinically symptomatic heart failure increased by 5% for men and 7% for women per 1-unit BMI increase despite adjustments for demographics and known CAD risk factors. 140 The "obesity paradox," whereby heart failure patients with higher BMIs have shown better survival rates than their leaner counterparts, has frequently been reported, raising questions as to whether surgical weight loss will prove beneficial in heart failure patients. [141] [142] [143] Chronic heart failure subjects who lost >6% of their body weight during the Studies of Left Ventricular Dysfunction (SOLVD) and Vasodilator-Heart Failure Trial II (V-HeFT II) trials showed excess mortality, although weight loss may reflect cardiac cachexia and disease progression in this advanced cohort. 144 The published experience of bariatric surgery in patients with preexisting heart failure is very limited, but some emerging data suggest that it is safe and effective. 145, 146 Obese individuals with predominantly systolic heart failure can experience dramatic improvements in symptoms and systolic function with weight loss. 147, 148 Available evidence supporting a role for bariatric surgery in reversing myocardial dysfunction in heart failure patients is currently limited to 2 small cohorts. One early study of vertical-band gastroplasty that included 13 patients with preoperative LV dysfunction demonstrated . 149 A subsequent 14-patient study of heart failure subjects with mildly reduced fractional shorting did not replicate these results. 150 Two additional studied reported on an overlapping cohort. 146, 151 Ramani et al 146 described 12 patients with a mean age of 41 years, BMI of 53 kg/m 2 , and LVEF of 22±7% and 10 matched control subjects who received diet and exercise counseling only. After 1 year, surgical patients showed improved LVEF (22±7% to 35±15%; P=0.005) and improved New York Heart Association functional class (2.9±0.7 to 2.3±0.5; P=0.02), with no improvement in control subjects.
Bariatric Surgery and Established CVD
In patients with established CAD, weight loss is associated with improved endothelial function and reduced risk of future cardiac events.
3,152-154 Plecka Östlund et al 155 showed a marked reduction in the hazard ratio for angina pectoris after gastric bypass but not with gastric volume reduction procedures (hazard ratio, from 3.8 to 2.04 in men and from 3.9 to 0.98 in women). Preliminary data from the Utah Obesity Study suggested that of 136 consecutive subjects returning for 5-year follow-up after gastric bypass, coronary artery calcium scores were markedly lower in postsurgical subjects than in a nonsurgical obese control group independently of traditional CVD risk factors. 156 Carotid intima-media thickness measured at baseline and after a 3-to 4-year interval demonstrated a rate of progression in a postgastroplasty group that was more in line with lean control subjects than with the 3-fold higher progression of patients who continued to be obese. 157 The findings from these 2 subclinical atherosclerosis assessment modalities raise the possibility that bariatric surgery may slow the progression of CAD.
Lopez-Jimenez et al 158 demonstrated the safety of RYGB in patients with preexisting CAD. There were no in-hospital deaths among the 52 clinical CAD patients (prior coronary revascularization, >30% angiographic stenosis, prior myocardial infarction, positive stress test) or 507 surgical patients without CAD. Three patients with CAD (5.8%; 95% CI, 0-12.2) and 7 patients without CAD (1.4%; 95% CI, 0.4-2.4) had cardiovascular complications (P=0.06). Of 6 patients with positive preoperative and postoperative stress tests, 1 patient received percutaneous coronary intervention and 4 patients showed decreased extension or severity of ischemia after bariatric surgery.
In addition, it has been observed that the risk of atrial and ventricular arrhythmias and of sudden cardiac death is elevated in obese individuals, possibly as a result of abnormal myocardial repolarization. Weight loss surgery appears to be associated with a decrease in the heterogeneity of ventricular repolarization 159 and may improve the QT interval and QT dispersion. 160, 161 Such electrophysiological modulation may reduce the substrate for ventricular arrhythmias in this high-risk patient population. P-wave dispersion, a marker of atrial refractoriness heterogeneity, was also shown to regress significantly after bariatric surgery, which has the potential to reduce atrial fibrillation burden in obese patients. 162 
Conclusions
Obesity is one of the greatest public health challenges of modern times, with the potential to negatively affect almost every organ system. The interactions between dysfunctional adipose tissue and metabolic disturbances such as diabetes mellitus, hypertension, hyperlipidemia, and inflammation are the probable mediators between obesity and CAD. Bariatric surgery can reverse many obesity-related disease processes, and there is now evidence supporting decreases in short-and medium-term cardiovascular outcomes. Data also suggest improved biventricular hypertrophy and diastolic dysfunction after bariatric surgery. Limited data suggest that surgical weight loss is safe and effective in carefully selected and medically optimized obese heart failure patients. The next step is ascertaining the long-term cardiovascular outcomes for obese patients who undergo bariatric surgery, particularly those with preexisting cardiac disease. Large randomized, controlled trials would be the ideal approach, although the sample size required given the relatively low cardiovascular and mortality event rates in the middle-aged and predominantly female obese population seeking bariatric surgery may be challenging to accommodate. Refinement of patient selection criteria to optimally identify patients who derive the most benefit from surgical weight loss is a prime challenge in the obesity field and requires ongoing scientific input from the cardiology community. However, the available literature already provides a solid platform from which cardiologists can initiate discussions with their obese patients about the role of bariatric surgery in cardiovascular event prevention.
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